ID: ALA4861833

Max Phase: Preclinical

Molecular Formula: C29H30ClN7O2

Molecular Weight: 544.06

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CN(C)C/C=C/C(=O)Nc1ccc(C(=O)N2CC[C@@H](Nc3ncc(Cl)c(-c4c[nH]c5ccccc45)n3)C2)cc1

Standard InChI:  InChI=1S/C29H30ClN7O2/c1-36(2)14-5-8-26(38)33-20-11-9-19(10-12-20)28(39)37-15-13-21(18-37)34-29-32-17-24(30)27(35-29)23-16-31-25-7-4-3-6-22(23)25/h3-12,16-17,21,31H,13-15,18H2,1-2H3,(H,33,38)(H,32,34,35)/b8-5+/t21-/m1/s1

Standard InChI Key:  GVUHDEMSKMOPHW-WKOQKXSESA-N

Associated Targets(Human)

CDK2/Cyclin A2 2260 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cyclin-dependent kinase 7/ cyclin H 714 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CDK9/cyclin T1 2643 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

CDK12/Cyclin K 892 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cyclin-dependent kinase 13/Cyclin-K 53 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 544.06Molecular Weight (Monoisotopic): 543.2150AlogP: 4.66#Rotatable Bonds: 8
Polar Surface Area: 106.25Molecular Species: BASEHBA: 6HBD: 3
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.74CX Basic pKa: 8.81CX LogP: 3.79CX LogD: 2.37
Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.28Np Likeness Score: -1.31

References

1. Jiang B, Jiang J, Kaltheuner IH, Iniguez AB, Anand K, Ferguson FM, Ficarro SB, Seong BKA, Greifenberg AK, Dust S, Kwiatkowski NP, Marto JA, Stegmaier K, Zhang T, Geyer M, Gray NS..  (2021)  Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.,  221  [PMID:33945934] [10.1016/j.ejmech.2021.113481]

Source